Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL ARTIFICIAL PANCREAS DEVICES SYSTEMS INDUSTRY
2.1 Summary about Artificial Pancreas Devices Systems Industry
2.2 Artificial Pancreas Devices Systems Market Trends
2.2.1 Artificial Pancreas Devices Systems Production & Consumption Trends
2.2.2 Artificial Pancreas Devices Systems Demand Structure Trends
2.3 Artificial Pancreas Devices Systems Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 CTR (Control to Range) Systems
4.2.2 CTT (Control to Target) Systems
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Medical Centres
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 CTR (Control to Range) Systems
5.2.2 CTT (Control to Target) Systems
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Medical Centres
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 CTR (Control to Range) Systems
6.2.2 CTT (Control to Target) Systems
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Medical Centres
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 CTR (Control to Range) Systems
7.2.2 CTT (Control to Target) Systems
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Medical Centres
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 CTR (Control to Range) Systems
8.2.2 CTT (Control to Target) Systems
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Medical Centres
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 CTR (Control to Range) Systems
9.2.2 CTT (Control to Target) Systems
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Medical Centres
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Medtronic
10.1.2 Bigfoot Biomedical
10.1.3 Beta Bionics
10.1.4 Admetsys
10.1.5 Insulet
10.1.6 Tandem Diabetes Care
10.1.7 Defymed
10.2 Artificial Pancreas Devices Systems Sales Date of Major Players (2017-2020e)
10.2.1 Medtronic
10.2.2 Bigfoot Biomedical
10.2.3 Beta Bionics
10.2.4 Admetsys
10.2.5 Insulet
10.2.6 Tandem Diabetes Care
10.2.7 Defymed
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
